Group 1 - Company shares of 华检医疗 (01931) have increased over 15%, with a cumulative rise of more than 120% in the month [1] - As of the report, the stock price is at 4.91 HKD, with a trading volume of 13.82 million HKD [1] - The company announced a strategic cooperation framework agreement with 华大共赢 to establish the IVD-BGI CoWin innovation drug intellectual property tokenization fund [1] Group 2 - The fund will invest in projects under the NewCo + RWA Web3 exchange ecosystem in Hong Kong, the US, or other overseas regions [1] - 华大共赢, initiated by the biotechnology leader 华大基因, has extensive investment experience and project resources in the innovative medical and pharmaceutical fields [1] - The company aims to address the pharmaceutical industry's pain points, where new drug development takes 10 years and 80% of funding is spent in clinical stages, by allowing ordinary investors access to high-value medical assets through RWA technology [1] Group 3 - The solution involves converting high-value medical assets, such as phase II clinical ADC drugs and gene therapy patents, into tradable digital certificates [1] - The goal is to become the "Nasdaq + Uniswap" in the medical RWA field, ensuring compliance while achieving decentralized liquidity [1]
港股异动 | 华检医疗(01931)再涨超15% 公司携手与华大共赢 建立创新药知识产权代币化基金